Biological markers in the etiology of psoriasis: Targeted treatment options.
Psoriasis is a common chronic and disabling inflammatory disease that has an enormous physical, functional and psychosocial impact on patients' quality of life. To date several conventional therapies are available for the treatment of this condition (eg, cyclosporine, methotrexate, retinoids, and psoralen plus ultraviolet A) which, although providing clinical response, do not maintain long-lasting disease remission and at times show poor tolerability with potential toxicity thus limiting their use. A challenge in psoriasis management is to utilize precociously an adequate therapy and to achieve effective and safe maintenance of its clearance by improving both skin and joint manifestations as well as to prevent joint destruction and disability. Recent improvement in the knowledge of the pathogenesis of this disease was fundamental for the development of novel targeted treatment options that may be effective, safer and well tolerated on long-term administration periods, thus improving patient's quality of life. These novel agents, which are called "biologics", target specifically tumor necrosis factor-alpha (infliximab, etanercept and adalimumab) or T cells (alefacept and efalizumab).
de Felice
Catia
C
San Gallicano Dermatological Institute, Rome, Italy.
Marulli
Georgiana Clare
GC
Ardigò
Marco
M
Berardesca
Enzo
E
J Am Acad Dermatol. 2006 Mar;54(3 Suppl 2):S85-91
16488334
J Invest Dermatol. 1999 Nov;113(5):752-9
10571730
Dermatol Ther. 2004;17(5):341-9
15379769
Health Technol Assess. 2000;4(40):1-125
11207450
Clin Exp Immunol. 1994 Apr;96(1):146-51
8149659
J Eur Acad Dermatol Venereol. 2003 Jul;17 Suppl 2:12-6
12795770
N Engl J Med. 2003 Nov 20;349(21):2014-22
14627786
Rev Gastroenterol Disord. 2004 Fall;4(4):196-210
15580154
Arthritis Rheum. 2005 Oct;52(10):3279-89
16200601
J Am Acad Dermatol. 2006 Mar;54(3 Suppl 2):S92-100
16488335
J Am Acad Dermatol. 2006 Mar;54(3 Suppl 2):S81-4
16488333
Hum Mol Genet. 1998;7(10):1537-45
9735374
J Am Acad Dermatol. 2002 Dec;47(6):821-33
12451365
Br J Dermatol. 2005 Jun;152(6):1304-12
15948997
J Am Acad Dermatol. 2007 Apr;56(4):598-603
17113190
Dermatol Ther. 2004;17(5):376-82
15379772
J Am Acad Dermatol. 2006 Mar;54(3 Suppl 2):S67-80
16488332
Arch Dermatol. 2003 Jun;139(6):719-27
12810502
Ann Rheum Dis. 2005 Mar;64 Suppl 2:ii87-90; discussion ii91-2
15708946
Br J Dermatol. 2000 Mar;142(3):401-12
10735943
Dermatology. 2004;208(4):297-306
15178911
J Am Acad Dermatol. 2007 Jan;56(1):31.e1-15
17097378
Arch Dermatol Res. 2006 Jun;298(1):7-15
16691429
J Am Acad Dermatol. 2005 Mar;52(3 Pt 1):425-33
15761420
Annu Rev Immunol. 1992;10:411-52
1590993
J Eur Acad Dermatol Venereol. 2003 Jul;17 Suppl 2:1-5
12795768
J Eur Acad Dermatol Venereol. 2003 May;17(3):257-70
12702062
Arthritis Rheum. 2005 Apr;52(4):1227-36
15818699
Lancet. 2005 Oct 15-21;366(9494):1367-74
16226614
Arch Dermatol. 2005 Jan;141(1):31-8
15655139
J Dtsch Dermatol Ges. 2006 Nov;4(11):947-56
17081270
J Am Acad Dermatol. 1984 Nov;11(5 Pt 2):937-47
6389615
Br J Dermatol. 2006 Jul;155(1):170-81
16792770
Br J Dermatol. 2005 Sep;153(3):486-97
16120132
Immunity. 2004 May;20(5):539-50
15142523
N Engl J Med. 2001 Jul 26;345(4):248-55
11474662
J Investig Dermatol Symp Proc. 2004 Mar;9(2):136-9
15083780
J Invest Dermatol. 2004 Mar;122(3):602-7
15086541